Burak Altintas, MD, an orthopedist with UTMB, who was not involved in this study, further highlighted the following limitations of the research: The limitations include retrospective design and likely residual confounding despite matching as fracture risk is influenced by many variables that are not reported [] Further, the comparison group is heterogeneous, combining another GLP-1 receptor agonist (dulaglutide) with two mechanistically different weight-loss medications
This leads to painful distension and bloating
More broadly, side effects follow a predictable pattern of being most prominent during the first 4-8 weeks of therapy and during each dose escalation
| How do you maintain weight loss after Wegovy
Chris and Rebecca are awesome
Losing weight takes pressure off your joints, leading to less pain and better movement